

# Renzhong Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9807214/publications.pdf>

Version: 2024-02-01

8  
papers

140  
citations

1937685

4  
h-index

1872680

6  
g-index

8  
all docs

8  
docs citations

8  
times ranked

287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1. <i>Future Medicinal Chemistry</i> , 2022, , .	2.3	0
2	Redirecting thromboxane A <sub>2</sub> and prostacyclin biosyntheses from thrombotic to antithrombotic property by an Enzymelink. <i>Future Medicinal Chemistry</i> , 2021, 13, 765-768.	2.3	0
3	Engineering Enzymelink™ for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity. <i>Future Medicinal Chemistry</i> , 2021, 13, 1091-1103.	2.3	5
4	Recent advances of cannabidiol studies in medicinal chemistry, pharmacology and therapeutics. <i>Future Medicinal Chemistry</i> , 2021, 13, 1935-1937.	2.3	3
5	Let-7a Is an Antihypertrophic Regulator in the Heart via Targeting Calmodulin. <i>International Journal of Biological Sciences</i> , 2017, 13, 22-31.	6.4	24
6	Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats. <i>Oncotarget</i> , 2017, 8, 20122-20132.	1.8	27
7	Cholesterol Retards Senescence in Bone Marrow Mesenchymal Stem Cells by Modulating Autophagy and ROS/p53/p21 <sup>Cip1/Waf1</sup> Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	4.0	36
8	Expression signature of lncRNAs and their potential roles in cardiac fibrosis of post-infarct mice. <i>Bioscience Reports</i> , 2016, 36, .	2.4	45